
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health has demonstrated a strong revenue performance in 4Q23, achieving $96.8 million, which surpassed earlier estimates and reflects a positive momentum driven by robust consumable sales. The company's average selling price (ASP) for total systems saw an impressive quarter-over-quarter growth of approximately 20%, reaching $28.8K, indicating an improved sales mix with a higher percentage of direct sales compared to prior periods. Additionally, the company's initial EBITDA guidance, while back-end weighted, aligns favorably above previous market expectations, suggesting potential for enhanced financial performance in future quarters.
Bears say
The Beauty Health Company reported a significant decline in new core delivery system placements, with a drop of over 30% year-over-year and quarter-over-quarter, coming in at 1,210 placements, which was notably below expectations. This deceleration in new system growth raises concerns about future consumables sales, essential for meeting profitability goals in 2024, despite strong performance in consumables during the fourth quarter of 2023. Furthermore, management's guidance for first-quarter 2024 indicated sales of $80 million and an adjusted EBITDA of negative $7.5 million, falling short of previous estimates and implying a challenging path to achieving the full-year EBITDA target of over $40 million.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares